Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on August 31, 2023, regarding Pharmacyte Biotech, Inc. (Nasdaq: PMCB). The filing documents the results of a Special Meeting of stockholders held on that date to approve corporate governance and capital structure amendments.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Corporate Actions
The filing details two primary actions approved by stockholders:
- Amendment to Articles of Incorporation: The total number of authorized common shares was increased from 133,333,334 to 200,000,000. The amendment was filed with the Nevada Secretary of State on September 6, 2023, with immediate effect.
- Authorization of Share Issuance: Stockholders authorized the issuance of shares underlying convertible preferred stock and warrants issued under a May 9, 2023 Securities Purchase Agreement. This authorization is required to comply with Nasdaq Listing Rule 5635(d) as the issuance exceeds 20% of the pre-issuance outstanding common stock.
Voting Results
A quorum was established with 11,422,363 shares (approximately 68.01% of outstanding shares) represented at the Special Meeting.
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| 1. Authorization of Issuance of Shares | 7,170,025 | 400,161 | 432,796 | 3,419,381 |
| 2. Approval of Increase of Authorized Shares | 9,982,019 | 1,019,080 | 421,264 | N/A |
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the standard disclosures related to the share issuance and charter amendment. The filing notes that the summary of the Amendment is qualified by reference to the full text attached as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the impact of the increased authorized share count (200,000,000) on potential future dilution.
- Review the May 9, 2023 Securities Purchase Agreement to understand the terms of the convertible preferred stock and warrants triggering the share issuance authorization.
- Confirm the effective date of the Charter Amendment (September 6, 2023) and its status with the State of Nevada.
- Note the significant number of broker non-votes (3,419,381) on Proposal 1, indicating shares held in street name where brokers lacked discretionary voting power.